VC Roundup: Relay Raises $57m To Seek Drug Targets Among Proteins In Motion
Relay launched with $57m to develop its novel technology platform for drug discovery based on protein motion with an initial focus on therapies for genetically defined cancers.
You may also be interested in...
Arteaus sells royalty stream from Lilly's Emgality giving investors a $260m payday. Also, Pfizer spin-out SpringWorks nabs another $125m, Arch Oncology and Prevail Therapeutics close $50m Series B rounds, and Karuna's recent financing grows to $80m.
Private Company Edition: Flagship ends 2017 with its biggest life science fund yet totaling $618m. Also, December sees a year-end surge in VC deals, including a $100m Series B round for Allakos.
A review of biopharma start-up dealmaking and financing from July through September 2016, based on data from Strategic Transactions.